221 related articles for article (PubMed ID: 35361554)
21. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma.
Bahlis NJ; Sutherland H; White D; Sebag M; Lentzsch S; Kotb R; Venner CP; Gasparetto C; Del Col A; Neri P; Reece D; Kauffman M; Shacham S; Unger TJ; Jeha J; Saint-Martin JR; Shah J; Chen C
Blood; 2018 Dec; 132(24):2546-2554. PubMed ID: 30352784
[TBL] [Abstract][Full Text] [Related]
22. Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma.
Syed YY
Target Oncol; 2023 Mar; 18(2):303-310. PubMed ID: 36622630
[TBL] [Abstract][Full Text] [Related]
23. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract][Full Text] [Related]
24. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Gandhi UH; Senapedis W; Baloglu E; Unger TJ; Chari A; Vogl D; Cornell RF
Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):335-345. PubMed ID: 29610030
[TBL] [Abstract][Full Text] [Related]
25. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Gasparetto C; Schiller GJ; Tuchman SA; Callander NS; Baljevic M; Lentzsch S; Rossi AC; Kotb R; White D; Bahlis NJ; Chen CI; Sutherland HJ; Madan S; LeBlanc R; Sebag M; Venner CP; Bensinger WI; Biran N; Ammu S; Ben-Shahar O; DeCastro A; Van Domelen D; Zhou T; Zhang C; Bentur OS; Shah J; Shacham S; Kauffman M; Lipe B
Br J Cancer; 2022 Mar; 126(5):718-725. PubMed ID: 34802051
[TBL] [Abstract][Full Text] [Related]
26. Selinexor: Targeting a novel pathway in multiple myeloma.
Mo CC; Yee AJ; Midha S; Hartley-Brown MA; Nadeem O; O'Donnell EK; Bianchi G; Sperling AS; Laubach JP; Richardson PG
EJHaem; 2023 Aug; 4(3):792-810. PubMed ID: 37601856
[TBL] [Abstract][Full Text] [Related]
27. Selinexor in multiple myeloma.
Martino EA; Vigna E; Bruzzese A; Labanca C; Mendicino F; Lucia E; Olivito V; Zimbo A; Torricelli F; Neri A; Morabito F; Gentile M
Expert Opin Pharmacother; 2024 Mar; 25(4):421-434. PubMed ID: 38503547
[TBL] [Abstract][Full Text] [Related]
28. Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series.
Remaggi G; Ochoa PA; Garate GM
Am J Case Rep; 2022 Jul; 23():e936505. PubMed ID: 35834427
[TBL] [Abstract][Full Text] [Related]
29. Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.
Magen H; Geva M; Volchik Y; Avigdor A; Nagler A
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e947-e955. PubMed ID: 32868229
[No Abstract] [Full Text] [Related]
30. Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas.
Goldsmith SR; Liu L; Shiah K
Curr Opin Oncol; 2022 Sep; 34(5):524-530. PubMed ID: 35880450
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of Selinexor: The First-in-Class Selective Inhibitor of Nuclear Export.
Bader JC; Abdul Razak AR; Shacham S; Xu H
Clin Pharmacokinet; 2021 Aug; 60(8):957-969. PubMed ID: 33928519
[TBL] [Abstract][Full Text] [Related]
32. The 'comeback' of Selinexor: From toxic to tolerable.
Hashmi H; Green K
Curr Probl Cancer; 2022 Feb; 46(1):100789. PubMed ID: 34479762
[TBL] [Abstract][Full Text] [Related]
33. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1.
Kwanten B; Deconick T; Walker C; Wang F; Landesman Y; Daelemans D
Biomed Pharmacother; 2023 Apr; 160():114305. PubMed ID: 36731340
[TBL] [Abstract][Full Text] [Related]
34. Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis.
Gu X; Sun C; Xu J; Lin Z; Zhang L; Zheng Y
Hematology; 2023 Dec; 28(1):2187972. PubMed ID: 36920065
[TBL] [Abstract][Full Text] [Related]
35. Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
Tremblay G; Daniele P; Breeze J; Li L; Shah J; Shacham S; Kauffman M; Engelhardt M; Chari A; Nooka A; Vogl D; Gavriatopoulou M; Dimopoulos MA; Richardson P; Biran N; Siegel D; Vlummens P; Doyen C; Facon T; Mohty M; Meuleman N; Levy M; Costa L; Hoffman JE; Delforge M; Kaminetzky D; Weisel K; Raab M; Dingli D; Tuchman S; Laurent F; Vij R; Schiller G; Moreau P; Richter J; Schreder M; Podar K; Parker T; Cornell RF; Lionel K; Choquet S; Sundar J
BMC Cancer; 2021 Sep; 21(1):993. PubMed ID: 34488662
[TBL] [Abstract][Full Text] [Related]
36. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
Benkova K; Mihalyova J; Hajek R; Jelinek T
Blood Rev; 2021 Mar; 46():100758. PubMed ID: 32972802
[TBL] [Abstract][Full Text] [Related]
37. Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HORIZON for the Treatment of Patients With Triple-Class Exposed Relapsed or Refractory Multiple Myeloma.
Weisel K; Krishnan A; Schecter JM; Vogel M; Jackson CC; Deraedt W; Yeh TM; Banerjee A; Yalniz F; Nesheiwat T; Van Sanden S; Diels J; Valluri S; Usmani SZ; Berdeja JG; Jagannath S; Martin T
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):690-701. PubMed ID: 35764490
[TBL] [Abstract][Full Text] [Related]
38. Selinexor in relapsed/refractory multiple myeloma.
Richter J; Madduri D; Richard S; Chari A
Ther Adv Hematol; 2020; 11():2040620720930629. PubMed ID: 32566115
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract][Full Text] [Related]
40. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Richard S; Chari A; Delimpasi S; Simonova M; Spicka I; Pour L; Kriachok I; Dimopoulos MA; Pylypenko H; Auner HW; Leleu X; Usenko G; Hajek R; Benjamin R; Dolai TK; Sinha DK; Venner CP; Garg M; Stevens DA; Quach H; Jagannath S; Moreau P; Levy M; Badros A; Anderson LD; Bahlis NJ; Facon T; Mateos MV; Cavo M; Chang H; Landesman Y; Chai Y; Arazy M; Shah J; Shacham S; Kauffman MG; Grosicki S; Richardson PG
Am J Hematol; 2021 Sep; 96(9):1120-1130. PubMed ID: 34062004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]